Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
It has previously been established that DDRs play
2020-06-29

It has previously been established that DDRs play an important role in collagen regulation in at least two distinct ways: (1) activation of DDRs by collagen results in up-regulation of the matrix metalloproteinases, which results in cleavage and degradation of the ECM20., 21., [22] and (2) epz of D
-
Three kinase inhibitors dasatinib type I imatinib type II an
2020-06-29

Three kinase inhibitors dasatinib (type I), imatinib (type II) and nilotinib (type II), identified initially as inhibitors of tyrosine kinase BCR-ABL, were found to target DDRs in a chemical proteomic profiling study (Bantscheff et al., 2007, Hantschel et al., 2008). These tyrosine kinase inhibitors
-
At baseline mutant allele frequency of
2020-06-29

At baseline, mutant allele frequency of EGFR in tissue and plasma samples did not correlated with anti-tumor response (Supplementary Fig. 1). Among 35 patients who were positive for cell-free DNA (cfDNA) at baseline, changes of cfDNA during treatment were analyzed. Negative conversion (NC) of cfDNA
-
The Lysine mutant is located in the tail
2020-06-29

The Lysine429 mutant is located in the tail region of 5-HT2A, which is predicted to be unstructured. This region has been shown to interact, in vitro, with PSD95 and leads to differences in signaling (Xia et al., 2003). The ASK motif, a component of the tail region, is also important for regulation
-
Typical examples of CO utilization and
2020-06-28

Typical examples of CO2 utilization and reduction technologies are catalytic reduction of CO2 to C1 compounds such as CO, formic acid, methanol and so on [[3], [4], [5], [6], [7], [8], [9], [10]], and catalytic organic synthesis using CO2 as a feedstock [[11], [12], [13], [14], [15], [16], [17], [18
-
br Results br Discussion The sequence homology based cluster
2020-06-28

Results Discussion The sequence homology-based clustering of the human kinome by Manning et al. (2002) has been extremely useful to organize kinases into Adenosine by sequence relationship. Since kinases are such prominent drug targets, we expect that clustering of the kinases by their inhibi
-
AQP protein expression was determined by Western blot
2020-06-28

AQP4 protein expression was determined by Western blot analysis. Briefly, protein samples (50μg) from brains or astrocytes were separated by 12% SDS–polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. The membranes were reacted with a rabbit polyclonal antibody against AQ
-
Notably HSP expression is under
2020-06-28

Notably, HSP27 expression is under control of the tetrameric form of CK2 holoenzyme, as knockout or knockdown of the β regulatory subunit alone reproduces the same effects of targeting the α/α′ catalytic subunits. This observation discloses the possibility to use more specific drugs that affects onl
-
The nuclear receptor NR superfamily of ligand
2020-06-28

The nuclear receptor (NR) superfamily of ligand regulated transcription factors has proven to be a rich source of targets for the development of therapeutics for a wide range of human diseases. The NR3B subfamily known as the estrogen-related receptor (ERRα[NR3B1], ERRβ[NR3B2] and ERRγ[NR3B3]) regul
-
Nitrid oxide NO and its potential endogenous production as
2020-06-28

Nitrid oxide (NO) and its potential endogenous production as an endothelium-derived factor was the first gaseous molecule accepted to be a signaling mediator in the organism [4,5]. NO plays a key role in physiological regulation of the adrenergic receptors and exerts physiological functions in the
-
With respect to the muscle compartment only low protein
2020-06-28

With respect to the muscle compartment, only low protein expression of ASB9 has been detected in healthy human skeletal muscle [as reported in the Human Protein Atlas (HPA)], whereas high levels of Asb5 protein expression are detected in mammalian skeletal muscle, which appears to be important in th
-
br Results and Discussion br Experimental
2020-06-28

Results and Discussion Experimental Procedures Acknowledgments The ubiquitin–proteasome system (UPS) is important for biological processes such as protein degradation and protein function regulation. In general, poly-ubiquitinated proteins are degraded by proteasomes, and some proteins ac
-
br Author Contributions Statement br Conflicts of interest b
2020-06-28

Author Contributions Statement Conflicts of interest Acknowledgments We thank T. Ishii, H. Inaba, and S. Nakamura (Department of Cell Biology, TMDU) for kindly gifting BACCS and technical assistance; S. Kaneko, Y. Ishida, and R. Usumi (Department of Orthodontic Science, TMDU) for experiment
-
The possibility of harm with DPP inhibitors
2020-06-28

The possibility of harm with DPP-4 inhibitors in patients with clinically overt heart failure has been recently highlighted by the results of the VIVIDD (Vildagliptin in Ventricular Dysfunction Diabetes) trial (68), the only trial to date that has been designed to evaluate the effects of a DPP-4 inh
-
The field of synthetic cytokine biology continues to grow
2020-06-24

The field of synthetic cytokine biology continues to grow through molecular, physiological and pathophysiological insights, as well as via new methodical advances. The approval of chimeric antigen receptor (CAR) T cell immunotherapy by the US Food and Drug administration (FDA) in August 2017 for rel
16027 records 811/1069 page Previous Next First page 上5页 811812813814815 下5页 Last page